ReviewMolecular cancer2025
Emerging role of cancer-associated fibroblasts in the premetastatic niche.
Review in Molecular cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- The vascular niche: an orchestrator of the spatiotemporal dynamics of distant metastasis.Acta pharmacologica Sinica · 2026Review
- A Single-Cell Atlas of Uterine Carcinosarcoma from Diverse Ancestries.bioRxiv : the preprint server for biology · 2026Article
- Targeting phase separation: a new strategy to disrupt the stromal-immune axis in colorectal cancer.Cell communication and signaling : CCS · 2026Review
- The role of the intratumoral microbiota in breast cancer metastasis and immune regulation: mechanisms and therapeutic implications.Frontiers in immunology · 2026Review
- Regulatory T cells in the breast cancer tumor microenvironment: new mechanisms, potential therapeutic strategies and future perspectives.American journal of cancer research · 2026Review
- Fibroblast-immune crosstalk in oral squamous cell carcinoma: from tumor promotion to immune evasion.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years, tumor metastasis has become one of the major causes of high recurrence and mortality in cancer patients. Owing to multiorgan involvement, metastatic cancers are now clinically difficult to cure and often have a very poor prognosis. In recent years, an increasing number of studies have shown that the establishment of a premetastatic niche (PMN) is necessary for tumor metastasis. Cancer-associated fibroblasts (CAFs), which are closely related to tumor development, are deeply involved in regulating PMN establishment. By regulating EVs, metabolism and other pathways, CAFs actively shape microenvironmental characteristics, including inflammation, angiogenesis, increased vascular permeability, lymphangiogenesis, immunosuppression and extracellular matrix (ECM) remodeling. With the development of single-cell sequencing technology, our understanding of the role and significance of heterogeneous CAFs in the PMN has improved. Multiple therapeutic strategies targeting CAFs in the PMN have also been developed. This article focuses on the crosstalk of different subtypes of CAFs with other stromal cells, the mechanisms by which CAFs of different origins mediate PMN formation, and the emerging cancer therapeutic strategies by which CAFs have been targeted in recent years.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.